Europe is expected to hold dominant position in global nanobodies market, owing to the first
mover advantage. Marketing authorization application (MMA) to EMA for Caplacizumab was
filed by Ablynx in February 2017, and the company expects to get approval in 2018. If
approved, Europe will be the only market to have nanobodies commercially available. However,
North America is expected to show rapid growth in this market, as the company is planning to
file for biologic license agreement for the same product to U.S. FDA in 2018, and expects to
get approval from FDA by 2019. Once approved in U.S., the company may plan to reap the
maximum benefit out of it. Furthermore, the drug, Caplacizumab, is expected to have better
efficiency compared to both the available treatment (i.e. plasma exchange therapy and
immunosuppressant) for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
In Asia Pacific, Japan may take the lead as multiple products such as Caplacizumab,
Vobarilizumab, and ALX- 0171 has successfully gone through initial phase of clinical
development.
Nanobodies Market Restraint
Presently, there are no products in market, and more than two-third products in very early
phase of development, and these products have to go through various phases of clinical
development. Failure in clinical trials for these products or slow approval by the regulatory
bodies in the market may prove to be vital restraint in this market.
Browse Complete Report For More Information @
https://www.coherentmarketinsights.com/ongoing-insight/nanobodies-market-1680
Nanobodies Market Key Players
Ablynx (now part of Sanofi S. A.) is the key player in the global nanobodies market. Moreover,
the company is developing various products with leading biology companies such as Novo
Nordisk A/S, Merck & Co., Inc., Merck KGaA, AbbVie, Inc., and C.H. Boehringer Sohn AG &
Ko. KG.
About Coherent Market Insights
Coherent Market Insights is a prominent market research and consulting firm offering action-
ready syndicated research reports, custom market analysis, consulting services, and competitive
analysis through various recommendations related to emerging market trends, technologies, and
potential absolute dollar opportunity.
Contact Us
Mr. Shah